Your browser doesn't support javascript.
loading
A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.
Zhao, Lijun; Li, Shuhong; Wei, Xiaoyi; Qi, Xuexiu; Liu, Dong; Liu, Lei; Wen, Feiqiu; Zhang, Ji-Shuai; Wang, Feng; Liu, Ze-Lin; Cao, Yu J.
Affiliation
  • Zhao L; State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
  • Li S; State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
  • Wei X; State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
  • Qi X; State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
  • Liu D; State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
  • Liu L; Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen, China.
  • Wen F; Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China.
  • Zhang JS; The Shenzhen Pregene Biopharma Company, Ltd, Shenzhen, China.
  • Wang F; Key Laboratory of Protein and Peptide Pharmaceuticals, Beijing Translational Center for Biopharmaceuticals Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  • Liu ZL; Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen, China.
  • Cao YJ; State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China.
Blood ; 140(16): 1790-1802, 2022 10 20.
Article in En | MEDLINE | ID: mdl-35981465
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, B-Cell / Burkitt Lymphoma / Antibodies, Bispecific / Precursor Cell Lymphoblastic Leukemia-Lymphoma Limits: Humans Language: En Journal: Blood Year: 2022 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, B-Cell / Burkitt Lymphoma / Antibodies, Bispecific / Precursor Cell Lymphoblastic Leukemia-Lymphoma Limits: Humans Language: En Journal: Blood Year: 2022 Type: Article Affiliation country: China